Search

Displaying results 3491 - 3500 of 10000 in total
  1. Drug

    Peginterferon alfa-2b

    go.drugbank.com/drugs/DB00022
    ApprovedInvestigational

    Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852].

    Categories: Interferon Type I, Compounds used in a research, industrial, or household setting
  2. Target

    Beta-ketoacyl-[acyl-carrier-protein] synthase III

    go.drugbank.com/bio_entities/BE0003868
    TargetEnterococcus faecalis (strain ATCC 700802 / V583)

    Catalyzes the condensation reaction of fatty acid synthesis by the addition to an acyl acceptor of two carbons from malonyl-ACP. Catalyzes the first condensation reaction which initiates fatty acid synthesis and may therefore play a role...

    Synonyms: KAS III
  3. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    [A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.

  4. Drug

    Grepafloxacin

    go.drugbank.com/drugs/DB00365
    ApprovedWithdrawn

    Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. … Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States

    Categories: Topoisomerase II Inhibitors
  5. Drug

    Fosfomycin

    go.drugbank.com/drugs/DB00828
    ApprovedInvestigational

    [A230348] In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring. … Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by _Streptomyces fradiae_.

  6. Target

    Non-secretory ribonuclease

    go.drugbank.com/bio_entities/BE0001306
    TargetHumans

    This is a non-secretory ribonuclease. It is a pyrimidine specific nuclease with a slight preference for U. Cytotoxin and helminthotoxin. Selectively chemotactic for dendritic cells. Possesses a wide variety of biological activities

    Synonyms: RNase UpI-2
  7. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates … , resulting in a premature termination of the trial.

  8. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    It has been engineered to secrete GM-CSF, an immune stimulating hormone, which also serves as the adjuvant in cancer immunotherapy. … CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated in numerous preclinical studies.

  9. Drug

    Ropeginterferon alfa-2b

    go.drugbank.com/drugs/DB15119
    ApprovedInvestigational

    Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for … [A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN-α-2b in _Escherichia coli_ that has high tolerability and a long half-life.

    Categories: Interferon Type I
  10. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary … circulation and decrease elevated pressure in the blood vessels supplying blood to the lungs.

    Categories: Prostacyclin Receptor Agonist, Prostacyclin Receptor Agonists